276 related articles for article (PubMed ID: 16302731)
1. Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
Yamamoto M; Iwaasa M; Nonaka M; Tsugu H; Nabeshima K; Fukushima T
Anticancer Res; 2005; 25(6A):3715-23. PubMed ID: 16302731
[TBL] [Abstract][Full Text] [Related]
2. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.
Brandes AA; Tosoni A; Vastola F; Pasetto LM; Coria B; Danieli D; Iuzzolino P; Gardiman M; Talacchi A; Ermani M
Cancer; 2004 Nov; 101(9):2079-85. PubMed ID: 15372474
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study.
Ogawa K; Yoshii Y; Toita T; Saito A; Kakinohana Y; Iraha S; Sugimoto K; Tsuchida Y; Tamaki W; Adachi G; Hyodo A; Murayama S
Anticancer Res; 2006; 26(3B):2457-62. PubMed ID: 16821632
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment modality for anaplastic oligodendroglioma and oligoastrocytoma: a 10-year update of a phase II study.
Jeremic B; Milicic B; Grujicic D; Samardzic M; Antunovic V; Dagovic A; Aleksandrovic J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):509-14. PubMed ID: 15145170
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Yang SH; Hong YK; Yoon SC; Kim BS; Lee YS; Lee TK; Lee KS; Jeun SS; Kim MC; Park CK
Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
Abrey LE; Childs BH; Paleologos N; Kaminer L; Rosenfeld S; Salzman D; Finlay JL; Gardner S; Peterson K; Hu W; Swinnen L; Bayer R; Forsyth P; Stewart D; Smith AM; Macdonald DR; Weaver S; Ramsay DA; Nimer SD; DeAngelis LM; Cairncross JG
Neuro Oncol; 2006 Apr; 8(2):183-8. PubMed ID: 16524945
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
14. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
[TBL] [Abstract][Full Text] [Related]
15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
[TBL] [Abstract][Full Text] [Related]
17. [Acute signs and symptoms of toxicity due to the BOPP regimen (BCNU, vincristine, procarbazine, cisplatin) during treatment of high-grade astrocytoma].
Jeremić B; Grujicić D; Jevremović S; Mijatović Lj
Srp Arh Celok Lek; 1991; 119(9-10):256-8. PubMed ID: 1806994
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
[TBL] [Abstract][Full Text] [Related]
20. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89.
Kühl J; Müller HL; Berthold F; Kortmann RD; Deinlein F; Maass E; Graf N; Gnekow A; Scheurlen W; Göbel U; Wolff JE; Bamberg M; Kaatsch P; Kleihues P; Rating D; Sörensen N; Wiestler OD
Klin Padiatr; 1998; 210(4):227-33. PubMed ID: 9743957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]